How should losartan be dosed and titrated in adult patients, including elderly individuals, those with moderate or severe renal impairment, volume depletion, pregnancy, and heart failure with reduced ejection fraction?

Losartan Dose Management

Start losartan at 50 mg once daily in most adult patients with hypertension, titrate to 100 mg once daily if needed for blood pressure control, but reduce the starting dose to 25 mg once daily in patients with hepatic impairment or volume depletion. 1

Standard Dosing for Hypertension

For adult hypertensive patients, the evidence is clear:

• Initial dose: 50 mg once daily
• Titration: Increase to 100 mg once daily if blood pressure targets are not achieved
• Maximum dose: 100 mg daily (doses of 150 mg showed no additional benefit over 50-100 mg in clinical trials) 1

The 10 mg and 25 mg doses produced inconsistent trough responses at 24 hours and should not be used as maintenance therapy in adults 1. Twice-daily dosing at 50-100 mg/day gave consistently larger trough responses than once-daily dosing at the same total dose, so consider splitting the dose if blood pressure control is inadequate 1.

Add hydrochlorothiazide 12.5 mg if monotherapy is insufficient—this combination produces placebo-adjusted blood pressure reductions of 15.5/9.2 mmHg 1.

Elderly Patients

No dose adjustment is necessary based on age alone 1. Plasma concentrations of losartan and its active metabolite are similar in elderly and young hypertensive patients 1. In clinical trials, 391 patients (19%) were ≥65 years and 37 patients (2%) were ≥75 years, with no overall differences in effectiveness or safety compared to younger patients 1.

Use the standard 50 mg starting dose and titrate as needed 2.

Renal Impairment

No dose adjustment is required for mild-to-moderate renal impairment unless the patient is also volume depleted 1. This is a critical distinction that is often missed.

The pharmacokinetic data shows:

• Plasma concentrations and AUCs of losartan and its active metabolite increase by 50-90% in patients with creatinine clearance 30-74 mL/min 1
• Renal clearance is reduced by 55-85% for both losartan and its active metabolite 1
• However, these pharmacokinetic changes do not translate to clinically significant differences in blood pressure response 3

In a study of hypertensive patients with mild-to-moderate renal impairment treated with losartan 50 mg/hydrochlorothiazide 12.5 mg titrated to losartan 100 mg/hydrochlorothiazide 25 mg for 12 weeks, mean reductions in trough sitting diastolic and systolic blood pressure were 15.0 mmHg and 20.8 mmHg respectively, with no increase in drug-related adverse events 3.

Neither losartan nor its active metabolite can be removed by hemodialysis 1.

For severe renal impairment (GFR <30 mL/min), safety and effectiveness have not been established in pediatric patients, but adult data suggests the medication can be used with careful monitoring 1.

Volume Depletion

Start with 25 mg once daily in volume-depleted patients 1. This is explicitly stated in the FDA label to reduce the risk of hypotension. Volume depletion can occur from:

• Aggressive diuretic therapy
• Dietary salt restriction
• Diarrhea or vomiting
• Hemodialysis

After volume status is corrected, titrate to standard doses.

Hepatic Impairment

Start with 25 mg once daily in patients with mild-to-moderate hepatic impairment 1. The pharmacokinetic rationale is compelling:

• Plasma concentrations of losartan are 5 times higher in patients with alcoholic cirrhosis
• Plasma concentrations of the active metabolite are 1.7 times higher
• Total plasma clearance is reduced by 50%
• Oral bioavailability is doubled 1

Losartan has not been studied in severe hepatic impairment and should be avoided 1.

Pregnancy

Losartan is absolutely contraindicated in pregnancy 1, 4. When given in the second and third trimester, losartan is associated with serious fetal toxicity including:

• Oliguria
• Hypotension requiring exchange transfusion or dialysis
• Renal dysfunction
• Death 1

If pregnancy is detected, discontinue losartan immediately.

Heart Failure with Reduced Ejection Fraction (HFrEF)

For patients with HFrEF who are intolerant to ACE inhibitors, the dosing strategy differs significantly from hypertension:

Start with 50 mg once daily and titrate to 150 mg once daily for maximum benefit 5. This recommendation is based on the HEAAL trial, which demonstrated:

• 150 mg daily reduced the rate of death or admission for heart failure compared to 50 mg daily (HR 0.90,95% CI 0.82-0.99; p=0.027)
• Hospital admissions for heart failure were significantly reduced (HR 0.87,95% CI 0.76-0.98; p=0.025)
• All-cause mortality showed a trend toward benefit but did not reach statistical significance (HR 0.94,95% CI 0.84-1.04; p=0.24) 5

Important caveats for high-dose losartan in HFrEF:

• Renal impairment (454 vs 317 patients), hypotension (203 vs 145), and hyperkalemia (195 vs 131) were more common with 150 mg vs 50 mg 5
• Women may not benefit from high-dose losartan compared to men (interaction p=0.018), though this may be confounded by age, kidney function, and symptom severity 6
• Patients with poorer kidney function and severe heart failure symptoms (NYHA class III/IV) had poorer response to high-dose losartan 6

Current guidelines recommend ARBs (including losartan) as an alternative in HFrEF patients who cannot tolerate ACE inhibitors 7, though angiotensin receptor-neprilysin inhibitors (ARNIs) are now preferred over ARBs when tolerated 7, 8.

Practical Titration Algorithm

1. Assess baseline status: Check volume status, renal function, liver function, pregnancy status
2. Choose starting dose:
   • 25 mg if hepatic impairment or volume depletion
   • 50 mg for all other patients
3. Monitor at 1 month: Blood pressure, renal function, potassium
4. Titrate based on indication:
   • Hypertension: Increase to 100 mg if BP target not met
   • HFrEF: Increase to 150 mg unless contraindicated by renal dysfunction, hypotension, or hyperkalemia
5. Add hydrochlorothiazide 12.5 mg if monotherapy insufficient for hypertension 9, 1
6. Consider twice-daily dosing if once-daily dosing provides inadequate 24-hour control 1

Common Pitfalls to Avoid

• Do not reduce the dose in renal impairment unless volume depleted—this is a frequent error based on pharmacokinetic data that doesn't translate to clinical outcomes 1, 3
• Do not use 10 mg or 25 mg as maintenance doses in adults with hypertension—these doses have inconsistent efficacy 1
• Do not exceed 100 mg daily for hypertension—no additional benefit was demonstrated 1
• Do not assume women need lower doses—while some data suggests sex differences in HFrEF, this is likely confounded by other factors 6
• Do not forget to check for pregnancy before initiating or continuing therapy 1